Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 26, 2015
Pharmacy Choice - News - Generic Drugs - March 26, 2015

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 46     Next >>     Go To Page:

3/26/15 - 2014 Annual Report DTR 6.3.5 Disclosure
2014 Annual Report- DTR 6.3. 5 Disclosure March 26, 2015- Shire plc announces that the following documents have today been posted or otherwise made available to shareholders:* 2014 Annual Report* Notice of the 2015 Annual General Meeting* Form of Proxy In accordance with Listing Rule 9.6. 1, a copy of each of these documents has been uploaded to th
3/26/15 - ASBM Survey Reports Physicians' Views on Biosimilar Labeling [Health & Beauty Close - Up]
The Alliance for Safe Biologic Medicines released the results from a survey on physicians' priorities related to biosimilar labeling. "ASBM commends the FDA for their work to make biosimilars a reality for patients across the country," said Reilly. "We believe this data provides FDA with clear guideposts for what is necessary to foster physician
3/26/15 - Fosun Pharma Witnesses an Increase of 33.51% in its 2014 Net Profit by Strengthening its Core Competitiveness with Improved Strategic Deployment
China, Mar 26, 2015 On 24 March 2015, Fosun Pharmaceutical Co., Ltd., a leading healthcare company in the PRC, is pleased to announce its audited consolidated financial results for the year ended 31 December 2014. It is disclosed in the Company's annual report that in 2014, the Company recorded revenue of RMB 12,025.53 million, and net profit of
3/26/15 - Global Active Pharmaceutical Ingredients Market to Be Propelled by Development of Biogeneric Drugs
Transparency Market Research Report Added "Active Pharmaceutical Ingredients Market" to its database.Albany, NY 03/26/2015 The U.S. Food and Drug Administration describes active pharmaceutical ingredients as substances or mixture of substances that are used in the manufacturing of drugs. Upon production, active pharmaceutical ingredients gene
3/26/15 - IGI Laboratories, Inc. Announces First ANDA Submission Of 2015
IGI Laboratories, Inc., a New Jersey based specialty generic pharmaceutical company, today announced it has submitted its first abbreviated new drug application to the U.S. Food and Drug Administration of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to twenty-three. Jason Grenfell-Gardner, President and C
3/26/15 - Patient Advocates, Physicians, Pharmacists Unite to Support Unique Biosimilars Naming Policy
WASHINGTON, March 26, 2015/ PRNewswire-USNewswire/ On Tuesday, March 24, 2015, five advocacy groups representing a broad spectrum of physicians, pharmacists and patients the American Autoimmune Related Diseases Association, Biologics Prescribers Collaborative, the Hematology/Oncology Pharmacy Association, National Alliance for Hispanic Health
3/26/15 - SHIRE PLC - 2014 Annual Report DTR 6.3.5 Disclosure
2014 Annual Report- DTR 6.3. 5 Disclosure March 26, 2015- Shire plc announces that the following documents have today been posted or otherwise made available to shareholders:* 2014 Annual Report* Notice of the 2015 Annual General Meeting* Form of Proxy In accordance with Listing Rule 9.6. 1, a copy of each of these documents has been uploaded to th
3/26/15 - United States : AKORN launches Phenylephrine HCl Ophthalmic Solution, USP, 2.5% and 10% [TendersInfo (India)]
Expanding its generic and branded ophthalmic portfolio, American specialty pharmaceutical company Akorn has launched Phenylephrine HCl Ophthalmic Solution, USP, 2.5% and 10%. The company received the US Food and Drug Administration' s approval for a new drug application for the product, earlier in January. According to IMS Health, sales of Phenylep
3/25/15 - BIO Urges Governor Hickenlooper to Sign Bill That Ensures Patient Access to Interchangeable Biologic Medicines
By a News Reporter-Staff News Editor at Biotech Week The Biotechnology Industry Organization and the Colorado BioScience Association call upon Governor Hickenlooper to sign critical legislation to create a pathway for the substitution of interchangeable biologic medicines. The policies outlined in the bill align with BIO's principles on biologic.
3/25/15 - Global Biosimilars Market - Industry Trends, Size, Growth Analysis and Forecast to 2020
Persistence Market Research is released upcoming report on title "Biosimilars Market- Global Industry Analysis and Forecast to 2020". New York, NY 03/25/2015 Biosimilars or follow-on biologics are biopharmaceutical drugs that are similar to approved biological drugs. Biosimilars are different from other generic drugs in terms of raw material
3/25/15 - Kern Pharma Cuts Order Processing Time in Half with Esker's Cloud-Based Solution
Esker, a worldwide leader in document process automation solutions and pioneer in cloud computing, today announced it has been selected by Kern Pharma, a specialist in the development, manufacturing and marketing of pharmaceuticals, particularly generics, to automate its order management process. Esker s Order Processing solution has enabled Ker
3/25/15 - Public Citizen - Briefing
EVENT: Public Citizen holds a briefing on the Food and Drug Administration's proposed rule "to enable generic drug makers to update warning labels when they learn of new dangers." Gwen Moore, D- Wis.; Frank Ackerman, senior economist at the Massachusetts Institute of Technology and Synapse Energy; Tammy Gilbert, patient care assistant; Cynthia Pear
3/25/15 - Sun Pharma announces closure of merger deal with Ranbaxy
Sun Pharmaceutical Industries Ltd., today, begins the integration of Ranbaxy's business following the successful closure of its merger. The combined entity's manufacturing footprint covers 5 continents with products sold in over 150 nations with a stronger presence in US, India, Asia, Europe, South Africa, CIS& Russia and Latin America. Significa
3/24/15 - Coherus BioSciences Reports Fourth Quarter and Year End 2014 Financial and Operating Results [Cihan News Agency (Turkey)]
-Coherus BioSciences, Inc., a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the quarter and fiscal year ended December 31, 2014. Received milestone payments totaling $70.3 million under existing collaboration with Baxter Healthcare Corporation in..
3/24/15 - Global Steering Committee Advances Efforts for Quality Assurance [press release]
"We have an urgent responsibility to understand the scope and scale of threats to safe delivery of medicines, and to take decisive and coordinated action to prevent, detect and respond to issues that arise," said Norbert Hauser, the GSC's first Chairman, who is a former Inspector General of the Global Fund. The GSC's initial members include the Glo
3/24/15 - Patent Expiration to Propel the Global Biosimilar and Follow-on Biologics Market During the Forecast Period
Transparency Market Research Report Added "Biosimilar and Follow-On Biologics Market" to its database.Albany, NY 03/24/2015 One of the main factors driving the global biosimilar and follow-on biologics market is patent expiration. The expansion of the follow-on biologics market can be attributed to various regulatory and commercial developmen
3/24/15 - TAC March to Parliament On World TB Day
Activists from the Treatment Action Campaign marched on Parliament this morning to call for better leadership in tuberculosis treatment and prevention in South Africa. "Also on our agenda is the fast tracking of cheap generic drugs to be made available in South Africa for the treatment of multi- and extensively drug resistant strains of TB.
3/23/15 - Coherus BioSciences Reports Fourth Quarter and Year End 2014 Financial and Operating Results
Coherus BioSciences, Inc., a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the quarter and fiscal year ended December 31, 2014. In March 2015, the Company initiated a pivotal study, which, if positive, could support the filing of a 351 biologics
3/23/15 - IGI Laboratories, Inc. Appoints John Celentano to Board of Directors
IGI Laboratories, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced that it has appointed John Celentano to its Board of Directors. Mr. Celentano will also serve on the Company's Audit Committee. He has over 30 years of experience in the pharmaceutical industry, having held various senior leadership positions at.
3/23/15 - Mylan Launches Generic Antabuse Tablets
By a News Reporter-Staff News Editor at Pharma Business Week Mylan N.V. and Mylan Inc. announced the U.S. launch of Disulfiram Tablets USP, 250 mg and 500 mg, which is the generic version of Odyssey Pharmaceutical's Antabuse. Disulfiram Tablets USP, 250 mg and 500 mg, had U.S. sales of approximately $16.4 million for the 12 months ending December
3/23/15 - Mylan Launches Generic Subutex Sublingual Tablets
By a News Reporter-Staff News Editor at Pharma Business Week Mylan N.V. and Mylan Inc. announced the U.S. launch of Buprenorphine Hydrochloride Sublingual Tablets, 2 mg and 8 mg, which is the generic version of Reckitt Benckiser's Subutex Sublingual Tablets. Buprenorphine Hydrochloride Sublingual Tablets, 2 mg and 8 mg had U.S. sales of approxima
3/23/15 - New ASBM Survey Provides Physicians' Views on Biosimilar Labeling
The Alliance for Safe Biologic Medicines today released the results from a survey on physicians' priorities related to biosimilar labeling. His presentation addressed the recent approval of the first biosimilar medicine in the U.S. and the timeliness of the new survey data as FDA considers the multiple biosimilar applications said to be pending b
3/23/15 - People's Pharmacy: Soaring generic drug prices squeeze patients [The Charlotte Observer]
March 23 Q: Has anyone done some investigative journalism to expose why several generic medication prices have skyrocketed? Digoxin is a heart drug first sold in 1939. Last year, one person purchased a three-month supply for $12. Today, it's $99.99 at a major pharmacy chain.
3/23/15 - Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed
By a News Reporter-Staff News Editor at Pharma Business Week Prime Therapeutics LLC, a non-profit pharmacy benefit manager serving more than 26 million members, released the following statement responding to the U.S. Food and Drug Administration's approval of the first biosimilar to enter the U.S. market. "Today's U.S. Food and Drug Administrati
3/23/15 - Research and Markets Adds Report: Biosimilars (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 [Manufacturing Close - Up]
On September 9, 2013, Hospira's Inflectra and Celltrion's Remsima, which are both biosimilars of J&J's Remicade, were approved by the European Commission for marketing in the EU for multiple autoimmune diseases, including RA, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. The US-based generics company, Hospira
Articles(s): 1 - 25 of 46     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Lupus: What You Need to Know
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415